Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIR1-365 in severe COVID-19
NCT04622332Phase 1Completed
- Sponsor
- Sironax
- Start
- Dec 2020
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing SIR1-365 with Matching placebo (2 arms). Primary endpoint: Treatment-Emergent Adverse Events at 14 days. Started Dec 2020; status: completed.
02
Drugs
SIR1-365
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04622332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04622332.